Wells Fargo upgraded Edwards Lifesciences to Overweight from Equal Weight with a $94 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Early notable gainers among liquid option names on January 31st
- Edwards Lifesciences price target raised to $82 from $80 at RBC Capital
- Edwards Lifesciences downgraded to In Line from Outperform at Evercore ISI
- Edwards Lifesciences price target raised to $84 from $78 at Truist
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies